TY - JOUR
T1 - Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line
T2 - RC-165N/human telomerase reverse transcriptase
AU - Kim, K. H.
AU - Dobi, A.
AU - Shaheduzzaman, S.
AU - Gao, C. L.
AU - Masuda, K.
AU - Li, H.
AU - Drukier, A.
AU - Gu, Y.
AU - Srikantan, V.
AU - Rhim, J. S.
AU - Srivastava, S.
N1 - Funding Information:
We are thankful for the generous support of Dr David G McLeod, Director of the Center for Prostate Disease Research. We acknowledge the excellent technical support of Ms Soyon Oh and Ms Jennifer Regalia. Also, we are thankful for Dr Ossetrova from BioTraces Inc. for performing PSA detection with the Super-ELISA system. This research was supported by the Center for Prostate Disease Research Program through the Henry M Jackson Foundation for the Advancement of Military Medicine under contract number HU001-04-C-1502 (2004) with the Uniformed Services University. The opinions and assertions contained herein are the private views of the authors and are not to be considered as reflecting the views of the Henry M Jackson Foundation for the Advancement of Military Medicine or the US Department of Defense.
PY - 2007/3
Y1 - 2007/3
N2 - The majority of prostate epithelial cell lines stably expressing wild-type (wt) or mutant (mt) androgen receptor (AR) are derived from metastatic prostate cancers. Therefore, the wt AR-expressing RC-165N/ human telomerase reverse transcriptase (hTERT) cell line derived from the benign prostate tissue of an African-American patient provides a unique opportunity to assess the functional status of AR in a cellular context not studied before. Although androgen-induced expression of known androgen responsive genes such as PMEPA1, and NDRG1 was observed in RC-165N/hTERT, this cell line expresses prostate-specific antigen (PSA) at significantly lower levels. Chromatin immunoprecipitation assay revealed androgen-dependent binding of AR to androgen response elements of PSA, PMEPA1 and NDRG1 genes. Similarities, as well as differences were noted in the expression of androgen responsive genes between RC-165N/hTERT and LNCaP cells. Comprehensive evaluations of AR functions in RC-165N/hTERT cells suggest that whereas some features of known AR functions are maintained in this benign prostatic tissue-derived cell line, other AR functions are not retained. Objective evaluations of similar cell lines will lead to the understanding of AR functions in prostate growth and differentiation.
AB - The majority of prostate epithelial cell lines stably expressing wild-type (wt) or mutant (mt) androgen receptor (AR) are derived from metastatic prostate cancers. Therefore, the wt AR-expressing RC-165N/ human telomerase reverse transcriptase (hTERT) cell line derived from the benign prostate tissue of an African-American patient provides a unique opportunity to assess the functional status of AR in a cellular context not studied before. Although androgen-induced expression of known androgen responsive genes such as PMEPA1, and NDRG1 was observed in RC-165N/hTERT, this cell line expresses prostate-specific antigen (PSA) at significantly lower levels. Chromatin immunoprecipitation assay revealed androgen-dependent binding of AR to androgen response elements of PSA, PMEPA1 and NDRG1 genes. Similarities, as well as differences were noted in the expression of androgen responsive genes between RC-165N/hTERT and LNCaP cells. Comprehensive evaluations of AR functions in RC-165N/hTERT cells suggest that whereas some features of known AR functions are maintained in this benign prostatic tissue-derived cell line, other AR functions are not retained. Objective evaluations of similar cell lines will lead to the understanding of AR functions in prostate growth and differentiation.
UR - http://www.scopus.com/inward/record.url?scp=33847682624&partnerID=8YFLogxK
U2 - 10.1038/sj.pcan.4500915
DO - 10.1038/sj.pcan.4500915
M3 - Article
C2 - 17075604
AN - SCOPUS:33847682624
SN - 1365-7852
VL - 10
SP - 30
EP - 38
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 1
ER -